New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
08:07 EDTABMDAbiomed receives CE Mark for Impella RP
Abiomed announced it has received CE Marking approval in the European Union to market the Impella RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The Impella RP is not currently cleared for sale or use in the United States.
News For ABMD From The Last 14 Days
Check below for free stories on ABMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
17:06 EDTABMDTrial results from Abiomed RECOVER RIGHT show survival rate of 73%
Abiomed announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption study of the Impella RP System. The clinical trial results demonstrated a survival rate of 73% in the overall patient population. Overall, the survival rate was 73% in the entire population at 30 days. Cohort A showed a survival rate of 83.3% and Cohort B had a 58.3% survival rate at 30 days.
September 15, 2014
07:21 EDTABMDHeart Failure Society of America to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use